Endocrine Pharmacology Practice Questions

Q: Which oral hypoglycemic drug improves insulin sensitivity by activating AMP-activated protein kinase (AMPK) in type 2 diabetes?

Metformin. ***Metformin (Correct)*** - **Metformin** is a biguanide that primarily lowers blood glucose by activating **AMP-activated protein kinase (AMPK)**. - This activation improves **insulin sensitivity**, reduces hepatic glucose production, and decreases intestinal glucose absorption. - Metformin is the first-line oral agent for type 2 diabetes and works through AMPK-dependent mechanisms. *Glibenclamide (Incorrect)* - **Glibenclamide** is a sulfonylurea that stimulates insulin secretion from beta cells by blocking **ATP-sensitive potassium channels**. - It does not primarily improve **insulin sensitivity** or activate AMPK. - It works by increasing insulin release, not improving insulin action. *Pioglitazone (Incorrect)* - **Pioglitazone** is a thiazolidinedione (TZD) that improves **insulin sensitivity** by activating **peroxisome proliferator-activated receptor-gamma (PPAR-γ)** in adipose tissue. - While it enhances insulin sensitivity, its mechanism of action is distinct from AMPK activation. - This is an important distractor as it also improves insulin sensitivity but through a different pathway. *Acarbose (Incorrect)* - **Acarbose** is an alpha-glucosidase inhibitor that reduces post-prandial glucose levels by delaying carbohydrate digestion and absorption in the intestine. - It does not directly improve **insulin sensitivity** or act via the AMPK pathway. - It works by slowing glucose absorption, not by improving cellular insulin response.

Q: A 30-year-old woman inquires about the mechanism of action of oral contraceptive pills (OCPs). What is the PRIMARY mechanism by which OCPs prevent pregnancy?

They inhibit ovulation. ***They inhibit ovulation*** - Oral contraceptive pills (OCPs) primarily act by suppressing the **hypothalamic-pituitary-ovarian axis**, preventing the surge of **luteinizing hormone (LH)** required for ovulation. - The **estrogen and progestin** components in OCPs provide negative feedback, leading to inconsistent follicular development and the absence of a dominant follicle. *They increase uterine contractility* - OCPs generally **decrease uterine contractility** to prevent implantation, rather than increase it in a way that would expel a pregnancy. - Increased uterine contractility could potentially interfere with implantation, but this is not the primary mechanism of action of OCPs for preventing conception. *They alter the pH of the vagina* - OCPs do **not significantly alter the vaginal pH** as a primary mechanism for preventing pregnancy. - Changes in vaginal pH are more commonly associated with methods like spermicides or natural physiological variations, not hormonal contraception. *They promote the thickening of cervical mucus* - While OCPs do cause the **thickening of cervical mucus**, making it difficult for sperm to penetrate and reach the egg, this is a **secondary mechanism**. - The **primary and most effective mechanism** is the inhibition of ovulation.

Q: A patient with osteoporosis is given a drug that acts as a monoclonal antibody against RANK ligand (RANKL). Which drug is appropriate?

Denosumab. ***Denosumab*** - **Denosumab** is a **monoclonal antibody** that specifically targets and inhibits **RANKL**. - By binding to **RANKL**, denosumab prevents its interaction with **RANK** on osteoclast precursors and mature osteoclasts, thereby inhibiting osteoclast formation, function, and survival, leading to decreased bone resorption and increased bone density. *Alendronate* - **Alendronate** is a **bisphosphonate**, a class of drugs that inhibit **osteoclast activity** by embedding into the bone matrix and inducing osteoclast apoptosis. - Its mechanism of action is distinct from targeting RANKL. *Raloxifene* - **Raloxifene** is a **selective estrogen receptor modulator (SERM)**. - It acts as an **estrogen agonist** in bone, helping to prevent bone loss, but its mechanism does not involve direct RANKL inhibition. *Zoledronic acid* - **Zoledronic acid** is also a **bisphosphonate**, similar to alendronate, and is administered intravenously. - It inhibits bone resorption by inducing **osteoclast apoptosis** and interfering with the **mevalonate pathway**, not by blocking RANKL.

Q: What is the mechanism of action of bisphosphonates in the treatment of osteoporosis?

Inhibit osteoclast activity. ***Inhibit osteoclast activity*** - Bisphosphonates are analogs of **pyrophosphate** that bind to **hydroxyapatite crystals** in the bone matrix. - Once internalized by osteoclasts during bone resorption, they disrupt the **mevalonate pathway**, leading to osteoclast apoptosis and reduced bone breakdown. *Enhance calcium absorption* - This is primarily the role of **Vitamin D**, which promotes calcium uptake from the gut. - Bisphosphonates do not directly affect **intestinal calcium absorption**. *Stimulate osteoblast activity* - Drugs like **teriparatide** (a parathyroid hormone analog) are known to stimulate osteoblast function and new bone formation. - Bisphosphonates primarily act to reduce bone resorption, not directly stimulate **bone formation**. *Increase parathyroid hormone levels* - **Parathyroid hormone (PTH)** plays a key role in calcium homeostasis, and chronically elevated PTH can lead to bone resorption. - Bisphosphonates do not increase PTH levels; instead, they work independently to strengthen bone.

Q: Which antidiabetic drug works by increasing insulin sensitivity through the activation of the peroxisome proliferator-activated receptor-gamma (PPAR-γ)?

Pioglitazone. ***Pioglitazone*** - **Pioglitazone** is a **thiazolidinedione (TZD)** that exerts its effects by activating **PPAR-γ** receptors. - Activation of **PPAR-γ** leads to increased **insulin sensitivity** in peripheral tissues and the liver, reducing insulin resistance. *Glibenclamide* - **Glibenclamide** is a **sulfonylurea** that works by stimulating **insulin secretion** from pancreatic **beta cells**. - It binds to the **sulfonylurea receptor 1 (SUR1)** on the **ATP-sensitive potassium channel**, causing depolarization and insulin release, not increased insulin sensitivity. *Metformin* - **Metformin** is a **biguanide** that primarily reduces **hepatic glucose production** and slightly increases peripheral glucose uptake. - Its main mechanism involves activation of **AMP-activated protein kinase (AMPK)**, not **PPAR-γ**. *Acarbose* - **Acarbose** is an **alpha-glucosidase inhibitor** that delays the digestion and absorption of carbohydrates in the gastrointestinal tract. - It reduces postprandial glucose excursions by interfering with carbohydrate breakdown, rather than affecting insulin sensitivity directly.

Q: What is the first-line drug for osteoporosis in postmenopausal women?

Bisphosphonates. ***Bisphosphonates*** - **Bisphosphonates** are the **first-line treatment** for osteoporosis due to their proven efficacy in reducing fracture risk by inhibiting osteoclast activity. - They bind to bone mineral and are internalized by osteoclasts, leading to their **apoptosis** and decreased bone resorption. *OCP* - **Oral contraceptives (OCP)** are not used for treating established osteoporosis; they may have a minor protective effect against bone loss in premenopausal women but are not a primary therapeutic agent postmenopause. - OCPs primarily contain **estrogen and/or progestin** and are used for contraception and managing menstrual irregularities. *Raloxifene* - **Raloxifene** is a **selective estrogen receptor modulator (SERM)** that can be used for osteoporosis prevention and treatment, especially if there's a concern for breast cancer, but it is typically a second-line option. - Although it mimics estrogen's beneficial effects on bone, it does not have the same overall fracture reduction efficacy as bisphosphonates and can increase the risk of **venous thromboembolism**. *Strontium* - **Strontium ranelate** is an anti-osteoporotic agent that both inhibits bone resorption and promotes bone formation. - Its use has been limited due to concerns about serious side effects, including an increased risk of **cardiovascular events** and **venous thromboembolism**, making it a less favored option compared to bisphosphonates.

Q: Which of the following drugs is used in SIADH?

Tolvaptan. ***Tolvaptan*** - **Tolvaptan** is an **oral vasopressin V2-receptor antagonist** that promotes water excretion without affecting sodium, making it effective for **hyponatremia** associated with SIADH [1]. - It works by blocking the action of **antidiuretic hormone (ADH)** at the renal collecting ducts, increasing free water clearance and thus raising serum sodium levels [1].*Desmopressin* - **Desmopressin** is a synthetic analog of **ADH (vasopressin)**, which acts as a V2 receptor agonist [2]. - It is used to **increase water reabsorption** and is therefore contraindicated in SIADH, where ADH levels are already inappropriately high [1].*Von Willebrand factor* - **Von Willebrand factor** is a protein primarily involved in **hemostasis** and is used to treat **Von Willebrand disease** and **hemophilia A**. - It has no role in the management of SIADH, which is a disorder of water balance.*Terlipressin* - **Terlipressin** is a vasopressin analog that acts as a **V1 receptor agonist**, primarily causing splanchnic vasoconstriction. - It is used to treat **esophageal variceal bleeding** and **hepatorenal syndrome**, but it is not indicated for SIADH.

Q: What are the active ingredients in the NuvaRing contraceptive?

Ethinyl estradiol + Etonogestrel. ***Ethinyl estradiol + Etonogestrel*** - The NuvaRing (vaginal ring) contains a combination of **ethinyl estradiol** (an estrogen) and **etonogestrel** (a progestin). - These hormones work together to prevent ovulation, thicken cervical mucus, and thin the uterine lining, thereby preventing pregnancy. *Ethinyl estradiol + Drospirenone* - This combination of hormones is found in some **oral contraceptive pills** (e.g., Yaz, Yasmin), not the NuvaRing. - Drospirenone is a **progestin** with anti-mineralocorticoid activity. *Levonorgestrel* - **Levonorgestrel** is a progestin used alone in various contraceptive methods, such as **emergency contraception** (e.g., Plan B), some intrauterine devices (IUDs), and progestin-only pills. - It is not the sole active ingredient, nor is it combined with ethinyl estradiol, in the NuvaRing. *Levonorgestrel + Ethinyl estradiol* - This combination is found in many **combination oral contraceptive pills** and some contraceptive patches. - While it contains both an estrogen and a progestin, the specific progestin in NuvaRing is etonogestrel, not levonorgestrel.

Q: Which Selective Estrogen Receptor Modulator (SERM) is used in the treatment of Dysfunctional Uterine Bleeding (DUB)?

Ormiloxifene. ***Correct: Ormiloxifene*** - Ormiloxifene is a **selective estrogen receptor modulator (SERM)** specifically approved and used for the management of **dysfunctional uterine bleeding (DUB)**. - It works by acting as an **estrogen antagonist on the endometrium**, which influences the endometrial lining to regulate bleeding patterns and **reduce menstrual blood loss**. - Marketed as **Sevista/Saheli** in India. *Incorrect: Clomiphene* - Clomiphene is primarily used as an **ovulation inducer** in women with infertility due to anovulation [1]. - It acts by blocking estrogen receptors in the hypothalamus, thereby increasing the secretion of gonadotropins [1]. - Not indicated for treatment of DUB. *Incorrect: Raloxifene* - Raloxifene is indicated for the prevention and treatment of **postmenopausal osteoporosis** and the reduction of invasive breast cancer risk in certain high-risk women [1][2]. - It has estrogen-agonist effects on bone and antagonist effects on breast and uterine tissue [1][2]. - Not used for management of DUB. *Incorrect: Tamoxifen* - Tamoxifen is widely used in the treatment of **estrogen receptor-positive breast cancer** in both pre- and postmenopausal women [1][2]. - It acts as an estrogen antagonist in breast tissue but has **estrogen-agonist effects on the endometrium**, which can cause endometrial hyperplasia or cancer [1][2]. - Not indicated for DUB treatment.

Q: Norgestimate in OC pills has the following advantage?

Reduces acne and hirsutism. ***reduces acne and hirsutism*** - **Norgestimate** is a third-generation progestin known for its **low androgenic activity**, which helps to counteract the androgenic effects that can contribute to acne and hirsutism when combined with estrogen. - By minimizing androgenic side effects, norgestimate-containing oral contraceptive pills (OCPs) can improve skin conditions such as **acne** and unwanted hair growth (**hirsutism**), making them a preferred choice for patients with these concerns. *May reduce the risk of venous thrombosis* - While some progestins are associated with varying risks of venous thrombosis, norgestimate does not inherently **reduce** this risk compared to other progestins; in fact, all combined OCPs carry some increased risk. - The risk of **venous thromboembolism (VTE)** is primarily influenced by the estrogen component and the specific type and dose of progestin, but norgestimate is not specifically noted for reducing this risk. *Is generally more affordable than standard OC pills* - The cost of OCPs can vary widely based on brand, generic availability, and insurance coverage; norgestimate-containing pills are not inherently more affordable than other standard OCPs. - In some cases, newer formulations or brand-name versions of norgestimate-containing pills may even be **more expensive** than older, generic alternatives. *May have cardiovascular benefits* - Combined oral contraceptives, including those with norgestimate, generally do not offer **cardiovascular benefits** and may even increase the risk of cardiovascular events, particularly in women with pre-existing risk factors. - Long-term use of OCPs, especially in smokers or those with hypertension, can elevate the risk of conditions like **myocardial infarction** and **stroke**, rather than providing benefits.

Question 1

Which oral hypoglycemic drug improves insulin sensitivity by activating AMP-activated protein kinase (AMPK) in type 2 diabetes?

Accepted Answer

Metformin

Answer

Glibenclamide

Answer

Pioglitazone

Answer

Acarbose

Question 2

A 30-year-old woman inquires about the mechanism of action of oral contraceptive pills (OCPs). What is the PRIMARY mechanism by which OCPs prevent pregnancy?

Accepted Answer

They inhibit ovulation

Answer

They increase uterine contractility

Answer

They alter the pH of the vagina

Answer

They promote the thickening of cervical mucus

Question 3

A patient with osteoporosis is given a drug that acts as a monoclonal antibody against RANK ligand (RANKL). Which drug is appropriate?

Accepted Answer

Denosumab

Answer

Alendronate

Answer

Raloxifene

Answer

Zoledronic acid

Question 4

What is the mechanism of action of bisphosphonates in the treatment of osteoporosis?

Accepted Answer

Inhibit osteoclast activity

Answer

Enhance calcium absorption

Answer

Stimulate osteoblast activity

Answer

Increase parathyroid hormone levels

Question 5

Which antidiabetic drug works by increasing insulin sensitivity through the activation of the peroxisome proliferator-activated receptor-gamma (PPAR-γ)?

Accepted Answer

Pioglitazone

Answer

Glibenclamide

Answer

Metformin

Answer

Acarbose

Question 6

What is the first-line drug for osteoporosis in postmenopausal women?

Accepted Answer

Bisphosphonates

Answer

OCP

Answer

Raloxifene

Answer

Strontium

Question 7

Which of the following drugs is used in SIADH?

Accepted Answer

Tolvaptan

Answer

Desmopressin

Answer

Von Willebrand factor

Answer

Terlipressin

Question 8

What are the active ingredients in the NuvaRing contraceptive?

Accepted Answer

Ethinyl estradiol + Etonogestrel

Answer

Ethinyl estradiol + Drospirenone

Answer

Levonorgestrel

Answer

Levonorgestrel + Ethinyl estradiol

Question 9

Which Selective Estrogen Receptor Modulator (SERM) is used in the treatment of Dysfunctional Uterine Bleeding (DUB)?

Accepted Answer

Ormiloxifene

Answer

Clomiphene

Answer

Raloxifene

Answer

Tamoxifen

Question 10

Norgestimate in OC pills has the following advantage?

Accepted Answer

Reduces acne and hirsutism

Answer

May reduce the risk of venous thrombosis

Answer

Is generally more affordable than standard OC pills

Answer

May have cardiovascular benefits

Endocrine Pharmacology — MCQs

Endocrine Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?